Secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization.
Deficient angiogenesis after ischemia may contribute to worse outcome of peripheral arterial disease in patients with diabetes mellitus. Based on our previous work where we demonstrated that Secretoneurin (SN) is up-regulated under hypoxic conditions and enhances angiogenesis, we analyzed the therap...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3781158?pdf=render |
| _version_ | 1818387676724723712 |
|---|---|
| author | Wilfried Schgoer Markus Theurl Karin Albrecht-Schgoer Verena Jonach Bernhard Koller Daniela Lener Wolfgang M Franz Rudolf Kirchmair |
| author_facet | Wilfried Schgoer Markus Theurl Karin Albrecht-Schgoer Verena Jonach Bernhard Koller Daniela Lener Wolfgang M Franz Rudolf Kirchmair |
| author_sort | Wilfried Schgoer |
| collection | DOAJ |
| description | Deficient angiogenesis after ischemia may contribute to worse outcome of peripheral arterial disease in patients with diabetes mellitus. Based on our previous work where we demonstrated that Secretoneurin (SN) is up-regulated under hypoxic conditions and enhances angiogenesis, we analyzed the therapeutic potential of SN gene therapy using a model of severe hind limb ischemia in streptozotocin-induced diabetic mice (STZ-DM). After induction of hind limb ischemia, blood flow was assessed by means of laser Doppler perfusion imaging (LDPI) and increased blood perfusion in the SN-treated animal group was observed. These results were complemented by the clinical observation of reduced necrosis and by an increased number of capillaries and arterioles in the SN-treated animal group. In vitro, we found that SN is capable of promoting proliferation and chemotaxis and reduces apoptosis in HUVECs cultured under hyperglycemic conditions. Additionally, SN activated ERK, eNOS and especially AKT as well as EGF-receptor in hyperglycemic HUVECs. In conclusion, we show that SN gene therapy improves post-ischemic neovascularization in diabetic mice through stimulation of angiogenesis and arteriogenesis indicating a possible therapeutic role of this factor in ischemia-related diseases in diabetic patients. |
| first_indexed | 2024-12-14T04:13:44Z |
| format | Article |
| id | doaj.art-c22c599f8664481a81b61ce74ea718d4 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T04:13:44Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-c22c599f8664481a81b61ce74ea718d42022-12-21T23:17:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0189e7402910.1371/journal.pone.0074029Secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization.Wilfried SchgoerMarkus TheurlKarin Albrecht-SchgoerVerena JonachBernhard KollerDaniela LenerWolfgang M FranzRudolf KirchmairDeficient angiogenesis after ischemia may contribute to worse outcome of peripheral arterial disease in patients with diabetes mellitus. Based on our previous work where we demonstrated that Secretoneurin (SN) is up-regulated under hypoxic conditions and enhances angiogenesis, we analyzed the therapeutic potential of SN gene therapy using a model of severe hind limb ischemia in streptozotocin-induced diabetic mice (STZ-DM). After induction of hind limb ischemia, blood flow was assessed by means of laser Doppler perfusion imaging (LDPI) and increased blood perfusion in the SN-treated animal group was observed. These results were complemented by the clinical observation of reduced necrosis and by an increased number of capillaries and arterioles in the SN-treated animal group. In vitro, we found that SN is capable of promoting proliferation and chemotaxis and reduces apoptosis in HUVECs cultured under hyperglycemic conditions. Additionally, SN activated ERK, eNOS and especially AKT as well as EGF-receptor in hyperglycemic HUVECs. In conclusion, we show that SN gene therapy improves post-ischemic neovascularization in diabetic mice through stimulation of angiogenesis and arteriogenesis indicating a possible therapeutic role of this factor in ischemia-related diseases in diabetic patients.http://europepmc.org/articles/PMC3781158?pdf=render |
| spellingShingle | Wilfried Schgoer Markus Theurl Karin Albrecht-Schgoer Verena Jonach Bernhard Koller Daniela Lener Wolfgang M Franz Rudolf Kirchmair Secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization. PLoS ONE |
| title | Secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization. |
| title_full | Secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization. |
| title_fullStr | Secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization. |
| title_full_unstemmed | Secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization. |
| title_short | Secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization. |
| title_sort | secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization |
| url | http://europepmc.org/articles/PMC3781158?pdf=render |
| work_keys_str_mv | AT wilfriedschgoer secretoneuringenetherapyimprovesbloodflowinanischemiamodelintype1diabeticmicebyenhancingtherapeuticneovascularization AT markustheurl secretoneuringenetherapyimprovesbloodflowinanischemiamodelintype1diabeticmicebyenhancingtherapeuticneovascularization AT karinalbrechtschgoer secretoneuringenetherapyimprovesbloodflowinanischemiamodelintype1diabeticmicebyenhancingtherapeuticneovascularization AT verenajonach secretoneuringenetherapyimprovesbloodflowinanischemiamodelintype1diabeticmicebyenhancingtherapeuticneovascularization AT bernhardkoller secretoneuringenetherapyimprovesbloodflowinanischemiamodelintype1diabeticmicebyenhancingtherapeuticneovascularization AT danielalener secretoneuringenetherapyimprovesbloodflowinanischemiamodelintype1diabeticmicebyenhancingtherapeuticneovascularization AT wolfgangmfranz secretoneuringenetherapyimprovesbloodflowinanischemiamodelintype1diabeticmicebyenhancingtherapeuticneovascularization AT rudolfkirchmair secretoneuringenetherapyimprovesbloodflowinanischemiamodelintype1diabeticmicebyenhancingtherapeuticneovascularization |